Lyell Wealth Management LP grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 24.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,174 shares of the life sciences company’s stock after purchasing an additional 1,820 shares during the quarter. Lyell Wealth Management LP’s holdings in Illumina were worth $1,827,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in ILMN. Dimensional Fund Advisors LP increased its holdings in shares of Illumina by 3.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 264,925 shares of the life sciences company’s stock valued at $45,211,000 after acquiring an additional 9,017 shares during the period. KCG Holdings Inc. acquired a new position in shares of Illumina in the 1st quarter valued at $290,000. AQR Capital Management LLC increased its holdings in shares of Illumina by 58.9% in the 1st quarter. AQR Capital Management LLC now owns 109,234 shares of the life sciences company’s stock valued at $18,640,000 after acquiring an additional 40,477 shares during the period. Tudor Investment Corp ET AL acquired a new position in shares of Illumina in the 1st quarter valued at $289,000. Finally, Private Asset Management Inc. increased its holdings in shares of Illumina by 24.7% in the 2nd quarter. Private Asset Management Inc. now owns 10,152 shares of the life sciences company’s stock valued at $1,762,000 after acquiring an additional 2,010 shares during the period. 92.70% of the stock is currently owned by institutional investors.
Shares of Illumina, Inc. (NASDAQ ILMN) opened at $209.14 on Wednesday. Illumina, Inc. has a 1 year low of $119.37 and a 1 year high of $214.50. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41. The company has a market cap of $30,505.24, a PE ratio of 61.09, a P/E/G ratio of 3.45 and a beta of 0.74.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, topping the consensus estimate of $0.99 by $0.12. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The business had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. During the same period in the previous year, the firm earned $0.97 EPS. The business’s revenue for the quarter was up 17.6% compared to the same quarter last year. analysts anticipate that Illumina, Inc. will post 3.75 earnings per share for the current fiscal year.
ILMN has been the topic of a number of recent research reports. Leerink Swann reaffirmed an “outperform” rating and issued a $225.00 target price (up from $207.00) on shares of Illumina in a report on Tuesday, September 12th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $226.00 target price (up from $202.00) on shares of Illumina in a report on Monday, October 9th. Citigroup Inc. lifted their target price on shares of Illumina from $180.00 to $220.00 and gave the company a “neutral” rating in a report on Wednesday, October 25th. Bank of America Corporation lifted their target price on shares of Illumina from $215.00 to $240.00 and gave the company a “buy” rating in a report on Wednesday, October 25th. Finally, Janney Montgomery Scott upgraded shares of Illumina from a “sell” rating to a “neutral” rating in a research report on Monday, October 23rd. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $200.88.
ILLEGAL ACTIVITY NOTICE: This report was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://ledgergazette.com/2017/11/15/lyell-wealth-management-lp-boosts-position-in-illumina-inc-ilmn.html.
In related news, Director Jay T. Flatley sold 2,540 shares of the business’s stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $197.39, for a total value of $501,370.60. Following the completion of the transaction, the director now owns 539,176 shares of the company’s stock, valued at approximately $106,427,950.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jay T. Flatley sold 22,540 shares of the business’s stock in a transaction dated Tuesday, August 29th. The shares were sold at an average price of $195.21, for a total transaction of $4,400,033.40. Following the completion of the transaction, the director now directly owns 539,176 shares of the company’s stock, valued at approximately $105,252,546.96. The disclosure for this sale can be found here. Insiders sold a total of 167,964 shares of company stock worth $34,559,469 over the last quarter. Insiders own 1.60% of the company’s stock.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.